Study of imatinib treatment patterns and outcomes among US Veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia

Journal of Oncology Practice

Volumn 9, Issue 5, 2013, Pages

  Vander Velde, Nancy ^b   Chen, Lei ^b   Guo, Amy ^b   Sharma, Hari ^b   Marynchenko, Maryna ^b   Wu, Eric Q ^b   Liu, Jinan ^b   Yang, Heidi ^b   Shi, Lizheng ^a  

^a TULANE UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB;

ADULT; ARTICLE; BLOOD CELL COUNT; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHILADELPHIA CHROMOSOME POSITIVE CELL; TREATMENT OUTCOME; UNITED STATES; VETERAN; WORLD HEALTH ORGANIZATION;

AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 84892573636     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000822     Document Type: Article

References (31)

1. Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172, 1999 (Pubitemid 29325745)
2. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340: 1330-1340, 1999 (Pubitemid 29196596)
3. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010
4. Huang X, Cortes J, Kantarjian H: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118: 3123-3127, 2012
5. Kantarjian H, Cortes J: Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 29: 1512-1516, 2011
6. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99: 1928-1937, 2002 (Pubitemid 34525471)
7. National Comprehensive Cancer Network: National Comprehensive Cancer Network clinical practice guidelines in oncology: Chronic myelogenous leukemia. http://www.nccn.org
8. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006 (Pubitemid 44903745)
9. Hochhaus A, La Roseé P: Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 18: 1321-1331, 2004 (Pubitemid 39136739)
10. Jabbour E, Kantarjian HM, Jones D, et al: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113:2154- 2160, 2009
11. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001 (Pubitemid 32743979)
12. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119: 1123-1129, 2012
13. Kantarjian HM, Hochhaus A, Saglio G, et al: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome- positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12: 841-851, 2011
14. Weisberg E, Manley PW, Cowan-Jacob SW, et al: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345-356, 2007 (Pubitemid 46652483)
15. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260- 2270, 2010
16. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010
17. Kantarjian HM, Giles FJ, Bhalla KN, et al: Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117: 1141-1145, 2011
18. Stone R, Kantarjian H, Baccarani M, et al: Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood (ASH Annual Meeting Abstracts) 110, 2007 (abstr 734)
19. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302, 2002
20. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26: 3358-3363, 2008
21. Steegman J, Michallet M, Morra E, et al: Imatinib use in chronic phase CML in clinical practice: The UNIC study. J Clin Oncol 26:15S, 2008 (suppl; abstr 7077)
22. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29: 1634-1642, 2011
23. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103: 553-561, 2011
24. Hochhaus A, O'Brien SG, Guilhot F, et al: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061, 2009
25. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-225, 2004
26. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035, 2010
27. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109: 58-60, 2007 (Pubitemid 46053043)
28. Lucas CM, Wang L, Austin GM, et al: A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22: 1963-1966, 2008
29. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551, 2006 (Pubitemid 43882350)
30. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531-2541, 2006 (Pubitemid 43882349)
31. SEER statistics: Chronic myeloid leukemia, National Cancer Institute. http:// seer.cancer.gov/statfacts/html/cmyl.html